Trial | NCT02529579  Report issue

Title

Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer

  • Phase

    Phase 1/Phase 2

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    187
The aim of this study is to evaluate the safety and efficacy of iAPA-DC/CTL combined gemcitabine therapy on advanced pancreatic cancer.
Study Started
Jun 30
2015
Primary Completion
Dec 31
2018
Anticipated
Study Completion
Dec 31
2019
Anticipated
Last Update
Aug 20
2015
Estimate

Other iAPA-DC/CTL adoptive cellular immunotherapy

twice DC cell infusion and CTL cell infusion for 6 times

Drug Gemcitabine

standard Gemcitabine therapy

Gemcitabine Active Comparator

Standard Gemcitabine Therapy

cellular immunotherapy & Gemcitabine Experimental

iAPA-DC/CTL adoptive cellular immunotherapy combined Standard Gemcitabine Therapy

Criteria 

Inclusion Criteria:

Advanced Pancreatic cancer patients with histological pathology confirmation
Both gender, aged 18-70 year-old
Bone marrow functioned well
Renal function normal
Liver function normal
patients are voluntary, and willing to sign informed consent
expected lifetime was at least 3 months

Exclusion Criteria:

With acute inflammation
Accompanied with primary malignant tumor other than pancreas
with autoimmune disease
using corticosteroid or other suppress immune hormone treatment
had transplant operation of vital organs
active hepatitis
HIV positive
dysfunction in blood coagulation
serious diseases in circulatory and respiratory systems
pregnancy or breast-feeding women
No Results Posted